dual PD-L1/PARP7 inhibitors (Hangzhou Haolu Pharma/ Hangzhou Normal University/ Shanghai University of Traditional Chinese Medicine)

N/A

Report date: 2025/06/11 10:36:28
NME

Base Information

Drug Namedual PD-L1/PARP7 inhibitors (Hangzhou Haolu Pharma/ Hangzhou Normal University/ Shanghai University of Traditional Chinese Medicine)
Drug Alias NameN/A
ClassificationSmall molecules
Mechanisms of ActionProgrammed death-ligand 1 blockersTCDD-inducible poly [ADP-ribose] polymerase inhibitors
TargetsProgrammed death-ligand 1TCDD-inducible poly [ADP-ribose] polymerase
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesHangzhou Normal University
China Registration ClassN/A

Develop Information

Active CompaniesHangzhou Normal UniversityHangzhou Haolu Pharmaceutical Technology Co., Ltd.Shanghai University Of Traditional Chinese Medicine
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A